scispace - formally typeset
A

Avi Ashkenazi

Researcher at Massachusetts Institute of Technology

Publications -  370
Citations -  48530

Avi Ashkenazi is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Receptor & Apoptosis. The author has an hindex of 98, co-authored 340 publications receiving 46279 citations. Previous affiliations of Avi Ashkenazi include University of California, San Francisco & Washington University in St. Louis.

Papers
More filters
Journal ArticleDOI

Death receptors: signaling and modulation

Avi Ashkenazi, +1 more
- 28 Aug 1998 - 
TL;DR: Apoptosis is a cell suicide mechanism that enables metazoans to control cell number in tissues and to eliminate individual cells that threaten the animal's survival.
Journal ArticleDOI

Safety and antitumor activity of recombinant soluble Apo2 ligand

TL;DR: Apo2L may have potent anticancer activity without significant toxicity toward normal tissues, and cooperated synergistically with the chemotherapeutic drugs 5-fluorouracil or CPT-11, causing substantial tumor regression or complete tumor ablation.
Journal ArticleDOI

Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family *

TL;DR: Results suggest that, along with other family members such as Fas/Apo-1 ligand and TNF, Apo-2L may serve as an extracellular signal that triggers programmed cell death.
Journal ArticleDOI

Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors

TL;DR: A cell surface mechanism exists for the regulation of cellular responsiveness to pro-apoptotic stimuli in tumor cells.
Journal ArticleDOI

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

TL;DR: Cancer cells often develop resistance to chemotherapy or irradiation through mutations in the p53 tumour-suppressor gene, which prevent apoptosis induction in response to cellular damage, so agents that are designed to activate death receptors or block decoy receptors might be used to kill tumour cells that are resistant to conventional cancer therapies.